Kidney & blood pressure researchJul 28, 2026

Changes in Blood Vessel Lining Cells in Chronic Kidney Disease: Causes and Possible Treatments

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 3, 2026

Abstract

Endothelial-to-mesenchymal transition (EndMT) is implicated in renal fibrosis, a major factor in chronic kidney disease progression.

EndMT involves endothelial cells transforming into cells with a fibrotic phenotype, contributing to kidney damage.
Transforming growth factor-β (TGF-β) is a key trigger for EndMT via multiple signaling pathways.
Additional pathways, including Wnt/β-catenin and Notch, influence EndMT in the context of kidney disease.
The precise quantitative role of EndMT in human chronic kidney disease progression is not fully understood.
Emerging therapies aim to inhibit EndMT and support kidney microvascular health.

Simplified

Renal fibrosis is the final common pathological outcome of chronic kidney disease (CKD) and a major driver of progression to end-stage kidney disease. Endothelial-to-mesenchymal transition (EndMT) is a phenotypic process in which endothelial cells lose their endothelial identity and acquire mesenchymal or myofibroblast-like characteristics, contributing to extracellular matrix accumulation, capillary rarefaction, microvascular dysfunction, and fibrotic remodeling. Transforming growth factor-β (TGF-β) is a central inducer of EndMT through both canonical Smad-dependent and non-canonical Smad-independent signaling pathways. Other pathways, including Wnt/β-catenin, Notch, Hedgehog, inflammatory cytokine signaling, autophagy dysregulation, oxidative stress, and metabolic reprogramming, further modulate EndMT in the diseased kidney. Despite growing evidence implicating EndMT in renal fibrosis, the quantitative contribution of EndMT to human CKD progression and the most effective therapeutic strategies to target this process remain incompletely defined. This review summarizes the cellular and molecular mechanisms of EndMT relevant to CKD, highlights key regulatory pathways and pathway crosstalk, and discusses emerging pharmacological approaches to limit EndMT, preserve microvascular integrity, and attenuate renal fibrogenesis.

Changes in Blood Vessel Lining Cells in Chronic Kidney Disease: Causes and Possible Treatments

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief